Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PBYI
PUMA BIOTECHNOLOGY, INC.
NASDAQ
$9.24
▲ UP 1.43% (0.13)

KEY STATISTICS

Market Cap$470.31 M
52w High$9.51
52w Low$4.30
Dividend Yield—
Frequency—
P/E15.15
Volume333.62K
Shares Out.50.90M

COMPANY

LEADERSHIP

Alan H. Auerbach
CHIEF EXECUTIVE
Alan H. Auerbach

COMPENSATION 2026

Salary$931,333
Stock Awards$551,549
Incentive Plan Pay$1,027,307
All Other Comp.$16,635
Total$3,062,337

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 24, 2012
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
179

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$57.50M
NOV
5
THU

PRICE

$9.24 ▲ UP 1.43% (+$0.13)
$9.15$9.30$9.459:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM9.24

About Puma Biotechnology, Inc.

https://www.pumabiotechnology.com ↗

Puma Biotechnology, Inc. develops and commercializes cancer treatments, including neratinib for HER2-positive breast cancer and solid tumors, through licensing agreements, headquartered in Los Angeles since 2010.

INDUSTRY

Biotechnology

A PRODUCT PUMA BIOTECHNOLOGY, INC. IS KNOWN FOR

NERLYNX® (neratinib)
NERLYNX® (neratinib)

NERLYNX, developed by Puma Biotechnology, is an oral medication for extended adjuvant treatment of early-stage HER2-positive breast cancer.

COMPETITORS

COMPETITOR
AZN COMPARE
LLY COMPARE
MRK COMPARE
NVS COMPARE
PFE COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$51.9M $59.88M ▲$41.96M ▼$53.56M ▲
Royalty$2.57M $15.57M ▲$2.85M ▼$2.94M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
85
LISTED HERE
19
RANKED BY POSITION SIZE
AVUV
0.07% · 2.2M
VTS.AX
0.00% · 1.3M
IWM
0.01% · 1.2M
DWAS
0.49% · 237.0K
BSVO
0.09% · 231.6K
FDM
0.46% · 211.3K
FESM
0.03% · 202.1K
DFAT
0.01% · 184.5K
R2SC.L
0.01% · 88.9K
GSSC
0.06% · 73.9K
EES
0.07% · 65.7K
ROSC
0.82% · 51.4K
XRS2.DE
0.01% · 40.0K
RSSL
0.01% · 21.0K
SQLV
0.30% · 13.5K
EB
EBI
0.01% · 5.4K
IVSS
0.10% · 3.1K
PQ
PQSG
0.18% · 2.7K
URTY
0.00% · 1.8K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
56.64%
HOLDERS
225
TOP 12 OF 225 · RANKED BY POSITION SIZE
Acorn Capital Advisors, LLC
4.1M sh · $21.94M
Vanguard Group Inc
3.8M sh · $22.6M
Blackrock, Inc.
3.6M sh · $21.67M
Blackrock Inc.
3.6M sh · $11.65M
Janus Henderson Investors Us LLC
2.2M sh · $82.19M
Renaissance Technologies LLC
2.2M sh · $11.42M
Acadian Asset Management LLC
2.1M sh · $10.9M
American Century Companies Inc
1.9M sh · $12.25M
Millennium Management LLC
1.5M sh · $9.44M
Dimensional Fund Advisors LP
1.4M sh · $9.17M
Athyrium Capital Management, LP
1.3M sh · $3.2M
Lsv Asset Management
1.2M sh · $7.56M

RATINGS SNAPSHOT

Overall rating: A

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity5
Return On Assets5
Debt To Equity4
Price To Earnings2
Price To Book2
Overall Score4

TRADES BY CONGRESS

HOUSE TRADES
Donna Shalala
Donna Shalala
Sale (Full)
2019-05-15

INSIDER TRADES

★
OFFICER: SEE REMARKS
HUNT DOUGLAS M
Sale · 8.5K shares
2026-07-06
★
DIRECTOR, 10 PERCENT OWNER, OFFICER: PRESIDENT AND CEO
AUERBACH ALAN H
Sale · 44.1K shares
2026-07-06
★
OFFICER: CHIEF FINANCIAL OFFICER
NOUGUES MAXIMO F
Sale · 9.4K shares
2026-07-06
★
DIRECTOR
Dorval Allison
Sale · 11.6K shares
2026-06-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
HOLD 1
1 GRADES IN THE LAST 12 MONTHS
TD Cowen HOLD

SECTORS PEERS

PEERPRICE
ALLO$2.09COMPARE
AVIR$5.43COMPARE
ARCT$13.45COMPARE
ABEO$6.09COMPARE
SGMT$10.25COMPARE
TRDA$7.57COMPARE
ELDN$3.45COMPARE
VYGR$3.39COMPARE